Mineralocorticoid Receptor Antagonism Improves Experimental Pulmonary Hypertension

被引：0
|
作者：
Preston, I. R. [1 ]
Sagliani, K. D. [1 ]
Warburton, R. [1 ]
Hill, N. S. [1 ]
Fanburg, B. L. [1 ]
Jaffe, I. Z. [1 ]
机构：
[1] Tufts Med Ctr, Boston, MA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4637
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension
    Preston, Ioana R.
    Sagliani, Kristen D.
    Warburton, Rod R.
    Hill, Nicholas S.
    Fanburg, Barry L.
    Jaffe, Iris Z.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2013, 304 (10) : L678 - L688
  • [2] Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats
    Tu, Ly
    Thuillet, Raphael
    Perrot, Julie
    Ottaviani, Mina
    Ponsardin, Emy
    Kolkhof, Peter
    Humbert, Marc
    Viengchareun, Say
    Lombes, Marc
    Guignabert, Christophe
    [J]. HYPERTENSION, 2022, 79 (10) : 2262 - 2273
  • [3] Mineralocorticoid receptor antagonism in experimental atherosclerosis
    Rajagopalan, S
    Duquaine, D
    King, S
    Pitt, B
    Patel, P
    [J]. CIRCULATION, 2002, 105 (18) : 2212 - 2216
  • [4] Temporary mineralocorticoid receptor antagonism during the development of hypertension improves cerebral artery dilation
    McClain, Jonathon L.
    Dorrance, Anne M.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2014, 239 (05) : 619 - 627
  • [5] Endothelin A receptor antagonism improves pulmonary and systemic hemodynamics in patients with severe pulmonary hypertension
    Apostolopoulou, SC
    Kyriakides, Z
    Webb, DJ
    Karavolias, G
    Kyrvassilis, G
    Kremastinos, DT
    Rammos, S
    [J]. CIRCULATION, 1999, 100 (18) : 551 - 551
  • [6] Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension
    Rossi, Gian Paolo
    Maiolino, Giuseppe
    [J]. HYPERTENSION RESEARCH, 2014, 37 (12) : 1029 - 1031
  • [7] Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension
    Gian Paolo Rossi
    Giuseppe Maiolino
    [J]. Hypertension Research, 2014, 37 : 1029 - 1031
  • [8] Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells
    Kowalski, Jessica
    Deng, Lisa
    Suennen, Chiara
    Koca, Duygu
    Meral, David
    Bode, Christoph
    Hein, Lutz
    Lother, Achim
    [J]. HYPERTENSION, 2021, 78 (02) : 456 - 465
  • [9] Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism
    Li, M
    Wen, C
    Fraser, T
    Whitworth, JA
    [J]. JOURNAL OF HYPERTENSION, 1999, 17 (03) : 419 - 426
  • [10] Proteinase-activated receptor 1 antagonism ameliorates experimental pulmonary hypertension
    Kuwabara, Yukimitsu
    Tanaka-Ishikawa, Mariko
    Abe, Kohtaro
    Hirano, Mayumi
    Hirooka, Yoshitaka
    Tsutsui, Hiroyuki
    Sunagawa, Kenji
    Hirano, Katsuya
    [J]. CARDIOVASCULAR RESEARCH, 2019, 115 (08) : 1357 - 1368
12345